HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
TUESDAY, April 2, 2019 (HealthDay News) -- For Medicare beneficiaries with mild cognitive impairment (MCI) or dementia of uncertain etiology, amyloid positron emission tomography (PET) is associated with changes in clinical management, according to a study published in the April 2 issue of the Journal of the American Medical Association.
Gil D. Rabinovici, M.D., from the University of California in San Francisco, and colleagues examined the correlation between amyloid PET and subsequent changes in clinical management for Medicare beneficiaries with MCI or dementia of uncertain etiology. A total of 16,008 patients were enrolled by 946 dementia specialists at 595 U.S. sites (71.3 percent completed study procedures and were included in the analyses). Diagnosis and management plans were documented before PET and 90 days after PET.
The researchers found that amyloid PET results were positive in 55.3 and 70.1 percent of patients with MCI and dementia, respectively. The composite end point (change in management between the pre- and post-PET visits) changed in 60.2 percent of patients with MCI and 63.5 percent of patients with dementia, exceeding the 30 percent threshold in each group. In 25.1 and 10.5 percent of patients, the etiologic diagnosis changed from Alzheimer disease to non-Alzheimer disease and from non-Alzheimer disease to Alzheimer disease, respectively.
"Further research is needed to determine whether amyloid PET is associated with improved clinical outcomes," the authors write.
Two authors disclosed financial ties to medical device companies, including General Electric Healthcare and Life Molecular Imaging, both of which partially funded the study.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at firstname.lastname@example.org with any questions.
Updated on May 27, 2022